A. von Deimling

This study identifies EMP3 as a regulator of EGFR/CDK2 signaling in glioblastoma by stabilizing EGFR and promoting its oncogenic activity.

This study shows that MHC class II antigen presentation on blood-borne myeloids is essential to maintain functional CD8+ T cells in brain tumors by preventing Tox-driven dysfunction.

This study shows that GW2580 reprograms M2-like glioblastoma-associated macrophages to M1-like cells, enhancing phagocytosis and T-cell killing, and reduces tumor cell proliferation in patient-derived organoids.

The paper maps the cellular origins of three common pediatric brain tumors using a single-nucleus atlas and transcriptome data, identifying lineage-specific origins and potential therapeutic targets.

This study identifies a distinct subset of pediatric gliomas with EGFR alterations, H3K27me3 loss, and broad tumor localization, suggesting EGFR inhibition as a potential therapy.

This paper shows G3BP1 anchors the TSC complex to lysosomes to suppress mTORC1 signaling without stress granules, and inhibits mTORC1-driven cancer and neuronal issues.

This study tests YM155 in 101 neuroblastoma cell lines, revealing ABCB1 and ABCC1 as mediators of resistance and highlighting cross-resistance differences between drug-adapted lines.